ArticleArchives of microbiology2026
Overexpression and process optimization for enhancing L-alanine production in E. coli BL21 (DE3).
Article in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The L-alanine boasts a plethora of industrial applications; however, its commercial utilization is hindered by high production costs, scarcity of raw materials, compromised fermentative productivity, and low enantiomeric purity. To address these challenges in amino acid biosynthesis, the present study employed a synthetic metabolic engineering strategy to enhance L-alanine production in the industrially robust Escherichia coli BL21 (DE3) strain. A synthetic alaD gene cassette, computationally designed and cloned into the pUC57 vector, was expressed under the control of a high-efficiency T7 promoter. Initial expression in recombinant E. coli BL21 (DE3) (alaD⁺) under unoptimized conditions resulted in modest L-alanine titres of 54.32 mM (4.84 g/L). However, through statistical optimization using Response Surface Methodology (RSM) and cultivation under oxygen-limited batch fermentation, the L-alanine yield increased markedly to 440.47 mM (39.24 g/L) within 24 h. Given its broad industrial applicability, this biosynthetic approach offers a promising and sustainable alternative to conventional chemical synthesis, positioning recombinant E. coli BL21 (DE3) (alaD⁺) as a viable microbial platform for commercial production of L-alanine.
Indexed as
Identifiers
42101480What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.